Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Hartmut Doehner, Anna Dolnik, Lin Tang, John F Seymour, Mark D Minden, Richard M Stone, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Valeria Santini, Paresh Vyas, CL Beach, Kyle J MacBeth, Barry S Skikne, Steve Songer, Nora Tu, Lars Bullinger, Herve Dombret
Leukemia | NATURE PUBLISHING GROUP | Published : 2018
Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients was assessed for gene mutations. Patients received azacitidine 75 mg/m2/day x7 days (n = 240) or conventional care regimens (CCR; n = 245): intensive chemotherapy, low-dose cytarabine, or best supportive care only. Overall survival (OS) was assessed for patients with common (occurring in ≥10% of patients) cytogenetic abnormalities and karyotypes, and for patients with recurring gene mutations. There was a significant OS improvement with azacitidine vs CCR for patients with European LeukemiaNet-defined Adverse karyo..View full abstract
The authors thank John Morrill and Jerry Weaver (Celgene Corporation) for assistance with data analysis. Editorial and administrative assistance was provided by Sheila Truten and Kelly Dittmore (Medical Communication Company, Inc.), sponsored by Celgene Corporation. This study was funded by Celgene Corporation.